Latest Biotech News

Novo Nordisk officially launched an oral formulation of its GLP‑1 obesity drug Wegovy in the U.S., listing insured patient copays as low as $25 per month and a cash price of $149 for starting...

A U.S. Court of Appeals affirmed a lower court injunction preventing the National Institutes of Health from imposing a 15% cap on indirect cost reimbursements to universities and research...

Researchers at St. Jude developed CHANGE‑seq‑BE, an unbiased, sensitive method to profile genome‑wide off‑target activity of CRISPR base editors to support safety evaluation in therapeutic...

Illumina released Connected Multiomics, a cloud‑based software suite that integrates multiomic data types with AI‑driven analytics and workflow automation to support scalable, connected biological...

Insilico Medicine completed a large Hong Kong IPO and immediately turned proceeds into a multiyear R&D tie‑up with Servier focused on oncology. The company raised roughly $292–293 million in the...

Pfizer and Cartography Biosciences struck a multiyear collaboration giving Pfizer options to license tumor‑selective antigens discovered with Cartography’s Atlas and Summit platforms. Pfizer...

Sanofi expanded its engagement with AI‑native Earendil Labs, signing a follow‑on agreement worth $160 million in upfront and near‑term payments and a broader collaboration framework that could...

Singapore‑based Deep Intelligent Pharma (DIP) closed a $50 million Series D to scale an AI platform that automates clinical trial design and execution. The company says its system decomposes...

Arrowhead Pharmaceuticals reported interim signals from RNAi candidates in obesity and announced plans to advance at least one program, ARO‑INHBE, into Phase 2 testing after early cohorts showed...

Novo Nordisk launched an oral form of semaglutide branded as Wegovy and started U.S. distribution with pricing tiers intended to expand access: as low as $25 per month for insured patients under...

Zenas Biopharma reported positive topline results from its Phase 3 Indigo trial of obexelimab in immunoglobulin G4‑related disease (IgG4‑RD) but investors reacted sharply after comparing effect...

U.K. biotech Ikarovec partnered with gene‑delivery specialist VectorBuilder to evaluate AAV capsids engineered to enable intravitreal delivery of an ocular gene therapy for intermediate...

Federal health officials announced an immediate reduction in the CDC’s routine pediatric vaccine recommendations to 11 diseases, a change implemented under HHS direction and outside the Advisory...

Researchers published two genome‑editing advances: St. Jude Children’s Research Hospital reported CHANGE‑seq‑BE, an unbiased method to map base‑editor off‑target activity and support safety...

Insilico Medicine completed an oversubscribed Hong Kong IPO and immediately converted that momentum into a multiyear oncology R&D collaboration with Servier. The company priced its listing and...

Deep Intelligent Pharma closed a $50 million Series D round to scale its AI-driven clinical trial automation platform. The financing was led by CDH Baifu with participation from existing backers...

Sanofi expanded its partnerships with AI-enabled discovery firms, announcing a large biotherapeutics collaboration with Earendil that could reach $2.56 billion and a separate near-term commitment...

Zenas Biopharma reported that obexelimab met the Phase III primary endpoint in the Indigo trial for IgG4‑related disease, demonstrating a statistically significant 56% reduction in flare risk...

Novo Nordisk began shipping an oral formulation of semaglutide marketed as a Wegovy pill in the U.S., with pharmacies filling prescriptions immediately. The company announced a tiered pricing...

Moderna submitted regulatory applications for its mRNA influenza vaccine, mRNA‑1010, to agencies in the U.S., Europe, Canada and Australia, seeking approval for use in adults aged 50 and older....